Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 401,251 | 611,091 | 1,132,054 | 1,355,947 |
| Cost and expenses: | ||||
| Cost of sales (excluding amortization of in-licensed rights) | 149,385 | 152,558 | 258,153 | 290,122 |
| Research and development | 91,258 | 204,392 | 245,218 | 977,840 |
| Selling, general and administrative | 107,600 | 137,897 | 216,551 | 271,526 |
| Litigation contingency charge | 39,000 | — | 39,000 | — |
| Amortization of in-licensed rights | 717 | 667 | 1,408 | 1,268 |
| Total cost and expenses | 387,960 | 495,514 | 760,330 | 1,540,756 |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s R&D?
- Sarepta Therapeutics, Inc. (SRPT) reported R&D of $91.26M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s R&D changed year-over-year?
- Sarepta Therapeutics, Inc.'s R&D decreased by 55.4% year-over-year, from $204.39M to $91.26M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Sarepta Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude